Uniform Civil Code: Khader asks union govt to discuss with Ulema

New Delhi: BJP leader Yogish Gowda, who was a member of the Dharwad Zilla Panchayath in Karnataka, was killed because of "political reasons", the CBI has alleged in its charge sheet filed against eight accused before a Dharwad court, officials said on Thursday.

Mr Gowda was killed on June 15, 2016 in front of a gym in Dharwad.

The charge sheet was filed before the Judicial Magistrate First Class Court in Dharwad against Santosh Savadatti, Dinesh M, Sunil KS, Harshith, Aswath S, Nazeer Ahamad, Shanawaz and Nutan K. All but one are in judicial custody.

"The accused allegedly came to Dharwad on two occasions in June 2016 and with the support of the other accused, allegedly planned the murder of Yogish Gowda. These accused fled after the crime," CBI spokesperson RK Gaur said.

The agency has alleged that the killing had "political reasons" behind it and was a result of political rivalry, the officials said.

The agency had taken over the case on September 24, 2019, nearly three years after the murder, on the request of the BJP government in Karnataka and a referral from the centre.

The case was earlier probed by the Karnataka Police which had charged six people for allegedly planning and executing the killing.

The CBI has arrested eight accused in the case of which seven are in judicial custody, they said.

"Further investigation into the role of the other accused and larger conspiracy in this case is continuing on a day-to-day basis," Mr Gaur said.

BJP leader murder caseYogish GowdaCentral Bureau of Investigation (CBI)

Bengaluru, Mar 9: Karnataka government has ordered holidays for children in lower and upper kindergarten classes in Bengaluru, in the wake of coronavirus outbreak and with positive cases being reported from states in its neighbourhood.

"Further to the advice received from the Health Commissioner, holidays have been declared for Lower and Upper Kindergarten classes in Bengaluru North, South and Rural districts due to coronavirus, " Karnataka Minister for Primary and Secondary Education S Suresh Kumar said on Sunday.

According to official estimates, no positive cases of coronavirus have been reported from Karnataka till now.

The state has strengthened all surveillance and containment measures against the possible spread of disease.

Till Sunday, 890 persons have been identified for observation including persons who have travelled to COVID-19 affected countries and contacts of COVID-19 positive cases.

Six persons have been admitted to selected isolation hospitals.

According to official estimates, till date 87,066 passengers have been screened at airports in Karnataka.

The number of COVID-19 cases in India climbed to 39 on Sunday with five people in Kerala testing positive for coronavirus. The deadly virus has caused the deaths of over 3300 people globally.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.